GH Research PLC Ordinary Shares GHRS
i
Market datapartial · fetched 2026-11-13T02:53:59.343Z
Delta surfaceAlpaca · derived absolute-delta buckets · 2026-11-20
Calculation methodologyOptions historyIV: ThetaData historical Greeks, equal-weight mean of call/put 50-delta IV across the next four listed Friday-cycle expirations, including holiday shifts verified against ThetaData’s market calendar. Missing inputs leave gaps. Skew: equal-weight mean of put minus call IV across those four expirations. IV-implied move history: mean of each expiration’s average call/put IV multiplied by the square root of remaining calendar days divided by 365.25; percentage of spot, not a quoted straddle premium.
History dataPriceAlpaca · sip · 2026-11-12T21:00:03.688716963Z
FundamentalsAlpha Vantage · unavailable
GH Research PLC Ordinary Shares options
Table
| Delta | Calls | Puts | ||||
|---|---|---|---|---|---|---|
| Pseudo strike | IV | B/E move | Pseudo strike | IV | B/E move | |
| 20Δ | 12.73 | 550.2% | 44.4% | |||
| 25Δ | 13.65 | 499.5% | 39.5% | |||
| 30Δ | 14.58 | 448.7% | 34.6% | |||
| 35Δ | 15.50 | 397.9% | 29.7% | |||
| 40Δ | 29.07 | 461.6% | 70.5% | 16.42 | 347.2% | 24.7% |
| 45Δ | 22.64 | 355.1% | 35.7% | 17.34 | 296.4% | 19.8% |
| 50Δ | 20.32 | 291.7% | 23.1% | 18.26 | 245.7% | 14.9% |
| 55Δ | 19.15 | 249.6% | 16.9% | 19.19 | 194.9% | 10.0% |
| 60Δ | 18.16 | 210.8% | 11.7% | |||
| 65Δ | 17.36 | 180.2% | 7.7% | |||
| 70Δ | 16.93 | 166.2% | 6.5% | |||
| 75Δ | 16.51 | 152.3% | 5.2% | |||
| 80Δ | 16.08 | 138.3% | 3.9% | |||
20Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 12.73
- IV
- 550.2%
- B/E move
- 44.4%
25Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 13.65
- IV
- 499.5%
- B/E move
- 39.5%
30Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 14.58
- IV
- 448.7%
- B/E move
- 34.6%
35Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 15.50
- IV
- 397.9%
- B/E move
- 29.7%
40Δ
- Pseudo strike
- 29.07
- IV
- 461.6%
- B/E move
- 70.5%
- Pseudo strike
- 16.42
- IV
- 347.2%
- B/E move
- 24.7%
45Δ
- Pseudo strike
- 22.64
- IV
- 355.1%
- B/E move
- 35.7%
- Pseudo strike
- 17.34
- IV
- 296.4%
- B/E move
- 19.8%
50Δ
- Pseudo strike
- 20.32
- IV
- 291.7%
- B/E move
- 23.1%
- Pseudo strike
- 18.26
- IV
- 245.7%
- B/E move
- 14.9%
55Δ
- Pseudo strike
- 19.15
- IV
- 249.6%
- B/E move
- 16.9%
- Pseudo strike
- 19.19
- IV
- 194.9%
- B/E move
- 10.0%
60Δ
- Pseudo strike
- 18.16
- IV
- 210.8%
- B/E move
- 11.7%
- Pseudo strike
- IV
- B/E move
65Δ
- Pseudo strike
- 17.36
- IV
- 180.2%
- B/E move
- 7.7%
- Pseudo strike
- IV
- B/E move
70Δ
- Pseudo strike
- 16.93
- IV
- 166.2%
- B/E move
- 6.5%
- Pseudo strike
- IV
- B/E move
75Δ
- Pseudo strike
- 16.51
- IV
- 152.3%
- B/E move
- 5.2%
- Pseudo strike
- IV
- B/E move
80Δ
- Pseudo strike
- 16.08
- IV
- 138.3%
- B/E move
- 3.9%
- Pseudo strike
- IV
- B/E move
Options history
Table
| Date | IV (%) |
|---|---|
| 82.70% | |
| 90.84% | |
| 95.00% | |
| 110.69% | |
| 71.00% | |
| 76.01% | |
| 70.00% | |
| 72.28% | |
| 72.51% | |
| 76.10% | |
| 80.67% | |
| 88.36% | |
| 81.21% | |
| 90.80% | |
| 134.19% | |
| 73.02% | |
| 71.96% | |
| 76.79% | |
| 69.23% | |
| 79.67% | |
| 76.50% | |
| 88.34% | |
| 90.91% | |
| 90.67% | |
| 102.51% | |
| 111.27% | |
| 124.01% | |
| 173.97% | |
| 224.93% | |
| 92.35% | |
| 92.00% | |
| 83.96% | |
| 90.90% | |
| 92.43% | |
| 95.89% | |
| 99.41% | |
| 98.60% | |
| 97.54% | |
| 91.36% | |
| 84.39% |
Biotechnology
GLUE
Description unavailable
More →GMAB
Genmab A / S develops antibody therapies for the treatment of cancer and other diseases mainly in Denmark. The company is headquartered in Copenhagen, Denmark.
More →GNLX
Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive…
More →GPCR
Structure Therapeutics Inc., a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet…
More →GRCE
Grace Therapeutics, Inc. engages in the development and commercialization of pharmaceutical products for rare and orphan diseases in Canada. The company is headquartered in…
More →GYRE
Gyre Therapeutics Inc. is a pioneering biopharmaceutical company at the forefront of developing advanced therapies for rare and complex diseases. Leveraging its proprietary…
More →